Liquidia Technologies (LQDA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT04691154[3] evaluates L606 inhalation suspension in Pulmonary Arterial Hypertension with a target enrollment of 28 participants. Trial NCT03992755[4] evaluates LIQ861 Inhaled Treprostinil in Primary Pulmonary Hypertension with a target enrollment of 92 participants.
LQDA has 5 Form 4 insider filings recorded at the SEC in the past 30 days[5].